Patients with metastatic urothelial carcinoma have significantly longer overall survival when treated with a combination of radiotherapy and chemotherapy compared with chemotherapy alone, a study found.
The presence of bone metastases is associated with shorter survival among patients who received single-agent immunotherapy for metastatic urothelial carcinoma.
A study of patients with metastatic upper tract urothelial carcinoma demonstrated that those who underwent cytoreductive surgery after chemotherapy had significantly improved survival compared with those who received chemotherapy alone.
Patients who receive treatment with immune checkpoint inhibitors for advanced renal cell carcinoma and urothelial carcinoma are more likely to experience disease progression and death if they have liver metastases, a study found.
In patients with high-risk tumors, those treated with segmental ureterectomy did not have worse overall survival compared with those who underwent radical nephroureterectomy.
As current guidelines only include a weak recommendation to offer perioperative chemotherapy to patients with muscle-invasive upper tract urothelial carcinoma, a new meta-analysis including evidence up to February 2020 provides potentially useful information.
Survival was significantly improved in patients with greater disease burden.
The 2020 update highlights the importance of accurate diagnosis of upper tract urothelial carcinoma, risk stratification, close follow-up of patients receiving kidney-sparing management, and other key aspects of care.
Patients who underwent ureteroscopic management of low-risk UTUC had a 5-year cancer-specific survival rate of 92.6%.
Overall and disease-free survival among patients undergoing surgical resection for MIUC is low despite increasing use of neoadjuvant chemotherapy.
